INKA Entworks Announces $8.2 Million Investment to Drive Global Expansion and AI-Driven Product Innovation
INKA Entworks, a global leader in video content security and mobile app security solutions, has secured $8.2 million in a funding round led by SV Investment, with co-investments from DSC Investment, Stonebridge Ventures, Inopolis Partners, and IBK Industrial Bank. This investment reinforces INKA Entworks' position as a market leader and sets the stage for significant growth and innovation in 2025 and beyond.
The funding will enable INKA Entworks to expand its portfolio of cutting-edge video content security and robust mobile app security Saas solutions. The company aims to deliver advanced revenue-securing technologies to key markets, including media, sports, banking, fintech, and retail, while also driving product enhancements leveraging AI capabilities. Additionally, the funding will accelerate INKA Entworks' expansion into the U.S. and European markets and bolster its recruitment efforts to attract top talent.
Lee Sung-min, Team Leader of SV Investment’s VC Division, commented, “It is remarkable that a domestic software company has achieved phenomenal growth with 60% of revenue coming from overseas. This investment will support INKA Entworks in securing major North American and European clients and solidifying its leadership in the video content and app security markets with AI-driven solutions.”
INKA Entworks has achieved an impressive compound annual growth rate (CAGR) of 43% in overseas sales over the past three years, underscoring its ability to scale effectively. The company’s innovative SaaS solutions PallyCon and AppSealing have been instrumental in preventing hacking and illegal duplication, earning the trust of content operators and mobile app developers worldwide. Its clientele includes prominent names such as DAZN, Schneider Electric, PCCW, VIU, Vidio, LGU+, Bajajfinsev, and Prasar Bharti showcasing its broad industry reach.
“As the first domestic company to provide mobile app and content security technologies in a SaaS format, we have contributed to the growth of the security industry,” said James Sungmin Ahn, CEO of INKA Entworks. “This investment will solidify our position in South Korea and propel our efforts to succeed globally.”
The company’s immediate focus includes enhancing product innovation, expanding its global reach, and strengthening its leadership to set new benchmarks in digital security, paving the way for a secure digital future.
About INKA Entworks
INKA Entworks is a global leader in content security and mobile app security solutions, providing innovative technologies to protect digital assets across industries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120715815/en/
Contacts
Media Contact:
Rupesh Shinde
obiz@inka.co.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 10:00:00 EET | Press release
With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global international showcase for food innovation, allowing brands and companies to ex
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom